Catalyst Crew Technologies Corp. (OTC: CCTC) announced the assignment of three Venezuelan patents to its wholly-owned subsidiary, Inversiones Long 33, C.A., as part of a strategy to align intellectual property with its operating structure. The patents, previously held by CEO Dr. Kevin Rodan Levy, cover proprietary technologies CardioAI, PulmoAI, and NeuroAI, which are designed for data-driven healthcare analytics, predictive modeling, and clinical decision-support applications.
The Company believes that consolidating IP at the subsidiary level enhances strategic flexibility, supports regulatory alignment, and may facilitate future partnerships, licensing opportunities, and regional expansion. Additionally, Catalyst Crew intends to pursue expanded IP protection in other jurisdictions worldwide to support long-term platform development and potential international deployment.
Dr. Kevin Rodan Levy stated: "Aligning our intellectual property within our operating structure is an important step as we continue building our platform. Establishing a clear foundation around our core technologies allows us to move forward with development, partnerships, and, where appropriate, broader intellectual property protection strategies across additional markets."
Catalyst Crew Technologies Corp. is an AI-driven healthcare technology company focused on emerging markets, with an initial emphasis on Latin America. The Company is developing scalable digital health solutions, including telehealth infrastructure, remote patient monitoring, and advanced healthcare analytics. More information is available at https://catalystcrewai.com and in the Company's SEC filings at www.sec.gov.
